---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-055962"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2026-08-12T12:18:05+00:00"
generated_at: "2026-08-12T12:20:06.637286+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Madrigal expands board to nine, appoints J&J R&D chief John C. Reed

## Summary
- Board grew from 8 to 9 members; Reed elected Class II director, term to 2027 annual meeting.
- Reed is EVP Innovative Medicine R&D at Johnson & Johnson, leading oncology, immunology, neuroscience research.
- Compensation: $50k cash retainer, $10k for Science & Tech Committee, $675k equity grant (50% options, 50% RSUs).
- Reed joins Science and Technology Committee; no material transactions disclosed under Item 404(a).

## SEC filing metadata
- accession: 0001628280-26-055962
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2026-08-12T12:18:05+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000162828026055962/0001628280-26-055962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000162828026055962/mdgl-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-055962
- JSON: https://secwatch.observer/filing/0001628280-26-055962.json
- Plain text: https://secwatch.observer/filing/0001628280-26-055962.txt

## Key facts
- Executive change
  John C. Reed was elected as Director at MADRIGAL PHARMACEUTICALS, INC..
  - Action: elected
  - Role: Director
  source text: On August 11, 2026, the Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August 11, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000162828026055962/0001628280-26-055962-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.